Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome

A. Benigni; P. Boccardo; M. Noris; G. Remuzzi; R. L. Siegler

doi:10.1016/0140-6736(92)90281-7

Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome

A. Benigni, P. Boccardo, M. Noris, G. Remuzzi, R. L. Siegler

Istituto di Ricerche Farmacologiche "Mario Negri"

Research output: Contribution to journal › Article › peer-review

Abstract

Since some of the features of haemolytic uraemic syndrome (HUS), such as platelet activation and glomerular injury, could be brought about by platelet-activating factor (PAF), we have studied the urinary excretion of PAF in 10 children with HUS and in 10 healthy age-matched controls. Urinary PAF concentrations, measured by radioimmunoassay, were significantly higher in acute-phase H US patients than in controls (mean 2·04 [SD 1·66] vs 0·72 [0·43] ng/mg creatinine, p <0·05) but were similar to those in controls in samples taken after recovery. High PAF concentrations during the acute phase of HUS may reflect platelet activation and glomerular injury; the lower values after recovery suggest that urinary PAF may be a marker of disease activity.

Original language	English
Pages (from-to)	835-836
Number of pages	2
Journal	Lancet
Volume	339
Issue number	8797
DOIs	https://doi.org/10.1016/0140-6736(92)90281-7
Publication status	Published - Apr 4 1992

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/0140-6736(92)90281-7

Fingerprint Dive into the research topics of 'Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome'. Together they form a unique fingerprint.

Cite this

@article{29f5a331f80248588c1e43233c6a3eeb,

title = "Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome",

abstract = "Since some of the features of haemolytic uraemic syndrome (HUS), such as platelet activation and glomerular injury, could be brought about by platelet-activating factor (PAF), we have studied the urinary excretion of PAF in 10 children with HUS and in 10 healthy age-matched controls. Urinary PAF concentrations, measured by radioimmunoassay, were significantly higher in acute-phase H US patients than in controls (mean 2·04 [SD 1·66] vs 0·72 [0·43] ng/mg creatinine, p <0·05) but were similar to those in controls in samples taken after recovery. High PAF concentrations during the acute phase of HUS may reflect platelet activation and glomerular injury; the lower values after recovery suggest that urinary PAF may be a marker of disease activity.",

author = "A. Benigni and P. Boccardo and M. Noris and G. Remuzzi and Siegler, {R. L.}",

year = "1992",

month = apr,

day = "4",

doi = "10.1016/0140-6736(92)90281-7",

language = "English",

volume = "339",

pages = "835--836",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Lancet Publishing Group",

number = "8797",

}

TY - JOUR

T1 - Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome

AU - Benigni, A.

AU - Boccardo, P.

AU - Noris, M.

AU - Remuzzi, G.

AU - Siegler, R. L.

PY - 1992/4/4

Y1 - 1992/4/4

N2 - Since some of the features of haemolytic uraemic syndrome (HUS), such as platelet activation and glomerular injury, could be brought about by platelet-activating factor (PAF), we have studied the urinary excretion of PAF in 10 children with HUS and in 10 healthy age-matched controls. Urinary PAF concentrations, measured by radioimmunoassay, were significantly higher in acute-phase H US patients than in controls (mean 2·04 [SD 1·66] vs 0·72 [0·43] ng/mg creatinine, p <0·05) but were similar to those in controls in samples taken after recovery. High PAF concentrations during the acute phase of HUS may reflect platelet activation and glomerular injury; the lower values after recovery suggest that urinary PAF may be a marker of disease activity.

AB - Since some of the features of haemolytic uraemic syndrome (HUS), such as platelet activation and glomerular injury, could be brought about by platelet-activating factor (PAF), we have studied the urinary excretion of PAF in 10 children with HUS and in 10 healthy age-matched controls. Urinary PAF concentrations, measured by radioimmunoassay, were significantly higher in acute-phase H US patients than in controls (mean 2·04 [SD 1·66] vs 0·72 [0·43] ng/mg creatinine, p <0·05) but were similar to those in controls in samples taken after recovery. High PAF concentrations during the acute phase of HUS may reflect platelet activation and glomerular injury; the lower values after recovery suggest that urinary PAF may be a marker of disease activity.

UR - http://www.scopus.com/inward/record.url?scp=0026600477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026600477&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(92)90281-7

DO - 10.1016/0140-6736(92)90281-7

M3 - Article

C2 - 1347859

AN - SCOPUS:0026600477

VL - 339

SP - 835

EP - 836

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8797

ER -